This case series explores Sandoz’s spin off from Novartis, which was finalized on 4 October 2023. Case A follows Richard Saynor’s (CEO, Sandoz) ruminations as he builds the company strategy in preparation for the board’s approval of Sandoz as a standalone company. The narrative outlines the key strategic areas that Richard, along with his senior leadership team, considered and which strategy was eventually approved by the board of directors (i.e. product portfolio mix), the direction of the growth strategy (i.e. top vs. bottom line approach), target geography regions and ownership model. Case A focuses on the dilemmas and considerations of each strategic area.
Learning Objective
- Understand the impact of accessibility and affordability of medicines on global health.
- Explore the global dynamics of the off-patent drugs industry.
- Recognize key opportunities and dilemmas of generics and biosimilar industries.
- Grasp the impact of strategic decisions on execution.
Keywords
Strategy, Leadership, Global Business, Generic Drug, Spin-off, Healthcare, Life Science, Board Conflict, Chief Executive Officer, Good Health, Well-being, Reduced Inequalities
Settings
World/global, Switzerland
Sandoz, Healthcare, Pharmaceuticals
2022-2024
Available Languages
English
Related material
Teaching note
IMD case studies are distributed through case clearing houses. In order to browse the collection and purchase copies please visit the links below.
Copyright Information
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
This case study is part of a series
-
Sandoz (A): Breaking free to stand alone
-
Sandoz (B): The art of staying true to your mission